These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33712343)

  • 1. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
    Shim KH; Kwon JE; Park SG; Choo SH; Kim SJ; Kim SI
    Urol Oncol; 2021 May; 39(5):298.e13-298.e20. PubMed ID: 33712343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
    Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
    Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence.
    Zupancic M; Pospihalj B; Cerovic S; Gazic B; Drev P; Hocevar M; Perhavec A
    Radiol Oncol; 2020 Apr; 54(2):194-200. PubMed ID: 32324163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
    Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
    Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
    Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
    Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
    Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
    Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
    Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
    Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
    Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G
    Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
    He J; Yi M; Tan L; Huang J; Huang L
    World J Surg Oncol; 2021 Jul; 19(1):215. PubMed ID: 34271938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
    Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
    Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
    Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
    Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
    Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.